Heron Therapeutics (HRTX) Assets Average (2011 - 2026)

Heron Therapeutics has reported Assets Average for 16 years, with the latest figure at $251.0 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 7.08% year-over-year to $251.0 million; the trailing twelve-month figure through Mar 2026 stood at $251.0 million (up 7.08% YoY), and the FY2025 full-year result was $244.5 million, up 7.32% from the prior year.
• Assets Average for Q1 2026 stood at $251.0 million, down from $252.4 million in the prior quarter.
• The five-year high for Assets Average was $289.7 million in Q1 2022, with the low at $211.1 million in Q2 2023.
• Historically, Assets Average has averaged $238.4 million across 5 years, with a median of $234.4 million in 2025.
• Annual changes were most pronounced in 2022 — Assets Average slumped 31.81% — and 2025, when it increased 11.21%.
• Heron Therapeutics' Assets Average stood at $261.5 million in 2022, then decreased by 13.62% to $225.9 million in 2023, then rose by 0.49% to $227.0 million in 2024, then grew by 11.21% to $252.4 million in 2025, then fell by 0.54% to $251.0 million in 2026.
• The last three Assets Average figures came in at $251.0 million (Q1 2026), $252.4 million (Q4 2025), and $240.5 million (Q3 2025), per Business Quant data.